Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1350974

Cover Image

PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1350974

Anti-infective Vaccines Market Report 2023-2033

PUBLISHED:
PAGES: 303 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Unprintable PDF (Single User) - 1 Year License
USD 4977
PDF (Team License - Up to 6 Users) - 1 Year License
USD 5670
PDF (Site License)
USD 6930
PDF (Enterprise License - Includes Free Datasets)
USD 8757

Add to Cart

The global Anti-infective Vaccines market is projected to grow at a CAGR of 6.6% by 2033.

“The Anti-infective Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Occurrence of New and Re-emerging Infectious Illnesses Driving Market Growth

The rapid spread of novel infectious illnesses, which can lead to global outbreaks, is a big concern. This is happening as people get closer to wild creatures, travel longer distances, and live in more congested regions than ever before. There is also concern that diseases may be deliberately transferred to people, animals, or plants as part of terrorist activities. COVID-19, SARS, MERS, Ebola, chikungunya, avian flu, swine flu, and Zika are among the 40 infectious diseases detected. Future pandemics and outbreaks, experts warn, could be much more catastrophic than COVID-19. Because these contagious diseases are becoming more widespread, there will be a higher need for vaccines in the coming years. This will result in increased financing for R&D, a robust pipeline of novel vaccines, and more alternatives for a wide spectrum of people. This will propel the market forward.

High Cost of Immunisation Vaccines Likely to Challenge Industry Growth

The development of a vaccine is an expensive process. Vaccines, unlike other pharmaceutical items, necessitate specialised equipment and monitoring devices, resulting in greater storage and distribution costs. Inadequate infrastructure for storage and distribution may jeopardise the effectiveness and quality of immunisation initiatives. The process from in vitro research to marketing takes 10-15 years and costs between $800 million and $1 billion. Furthermore, because vaccine development has a poor success rate, firms frequently struggle with managing operational expenses and attracting initial finance. As a result, the increased costs associated with vaccine development and storage are acting as a barrier to market expansion.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the anti-infective vaccines market evolving?
  • What is driving and restraining the anti-infective vaccines market?
  • How will each anti-infective vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each anti-infective vaccines submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading anti-infective vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the anti-infective vaccines projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of anti-infective vaccines projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the anti-infective vaccines market?
  • Where is the anti-infective vaccines market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the anti-infective vaccines market today, and over the next 10 years:

  • Our 303 page report provides 112 tables, 157 charts /graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the anti-infective vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising anti-infective vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vaccine Type

  • Seasonal Influenza
  • Shingles
  • Tdap containing /DTaP Primary Vaccine
  • Pneumococcal Conjugate Vaccine (PCV)
  • Human Papillomavirus (HPV)
  • Rotavirus
  • Varicella
  • Meningococcal
  • Other Vaccines

Application Type

  • Viral
  • Bacterial

End-users

  • Adult Vaccines
  • Pediatric Vaccines
  • Wide Ranging (Comprehensive) Vaccines

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-infective Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies profiled in the report:

  • AstraZeneca
  • Bavarian Nordic
  • BioDiem
  • CSL
  • Emergent
  • Evotec SE
  • Merck KGaA
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Sinovac
  • Valneva SE

Overall world revenue for anti-infective vaccines market, 2023 to 2033 in terms of value the market will surpass US$48,300 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Anti-infective Vaccines Market, 2023 to 2033 report help you?

In summary, our 300+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Anti-infective Vaccines, 2023 to 2033 Market, with forecasts for vaccine types, application types, and end-users types, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the Anti-infective Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, South Korea, Singapore, Brazil, Mexico, Argentina, Colombia, GCC, South Africa, and among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 11 of the major companies involved in the Anti-infective Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the anti-infective vaccines market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Product Code: PHA1283

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Anti-infective Vaccines Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Pandemic Preparedness Driving Anti-Infective Vaccine Growth: A Paradigm Shift in Global Health
      • 3.2.1.2 Increasing Prevalence of New and Re-emerging Infectious Diseases
      • 3.2.1.3 Rising Demand for Tailored Vaccination Strategies is Driving Market Expansion
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Substantial Expense of Immunization Vaccines Presents Notable Hindrances
      • 3.2.2.2 Lack of Access to Anti-infective Vaccines in Underdeveloped Regions
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Synergistic Collaboration Between Governments, International Health Organizations, and Vaccine Manufacturers
      • 3.2.3.2 Increasing Funding Catalysing Advances in Vaccines and Infectious Disease Research
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Anti-infective Vaccines Market Analysis by Vaccine Type

  • 4.1 Key Findings
  • 4.2 Vaccine Type Segment: Market Attractiveness Index
  • 4.3 Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 4.4 Seasonal Influenza
    • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Shingles
    • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)
  • 4.6 TdaP Containing /DTaP primary
    • 4.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.6.2 Market Share by Region, 2023 & 2033 (%)
  • 4.7 Pneumococcal Conjugate Vaccine (PCV)
    • 4.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.7.2 Market Share by Region, 2023 & 2033 (%)
  • 4.8 Human Papillomavirus (HPV)
    • 4.8.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.8.2 Market Share by Region, 2023 & 2033 (%)
  • 4.9 Rotavirus
    • 4.9.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.9.2 Market Share by Region, 2023 & 2033 (%)
  • 4.10 Varicella
    • 4.10.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.10.2 Market Share by Region, 2023 & 2033 (%)
  • 4.11 Meningococcal
    • 4.11.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.11.2 Market Share by Region, 2023 & 2033 (%)
  • 4.12 Other Vaccines
    • 4.12.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.12.2 Market Share by Region, 2023 & 2033 (%)

5 Anti-infective Vaccines Market Analysis by Application Type

  • 5.1 Key Findings
  • 5.2 Application Type Segment: Market Attractiveness Index
  • 5.3 Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 5.4 Viral
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Bacterial
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)

6 Anti-infective Vaccines Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 6.4 Adult Vaccines
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Paediatric Vaccines
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Wide Ranging (Comprehensive) Vaccines
    • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Anti-infective Vaccines Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America Anti-infective Vaccines Market Analysis

  • 8.1 Key Findings
  • 8.2 North America Anti-infective Vaccines Market Attractiveness Index
  • 8.3 North America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 8.4 North America Anti-infective Vaccines Market Size Estimation and Forecast by Country
  • 8.5 North America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 8.6 North America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 8.7 North America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 8.8 U.S. Anti-infective Vaccines Market Analysis
  • 8.9 Canada Anti-infective Vaccines Market Analysis

9 Europe Anti-infective Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe Anti-infective Vaccines Market Attractiveness Index
  • 9.3 Europe Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Country
  • 9.5 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 9.6 Europe Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 9.7 Europe Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 9.8 Germany Anti-infective Vaccines Market Analysis
  • 9.9 France Anti-infective Vaccines Market Analysis
  • 9.10 UK Anti-infective Vaccines Market Analysis
  • 9.11 Italy Anti-infective Vaccines Market Analysis
  • 9.12 Spain Anti-infective Vaccines Market Analysis
  • 9.13 Russia Anti-infective Vaccines Market Analysis
  • 9.14 Rest of Europe Anti-infective Vaccines Market Analysis

10 Asia Pacific Anti-infective Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
  • 10.3 Asia Pacific Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 10.6 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 10.7 Asia Pacific Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 10.8 Japan Anti-infective Vaccines Market Analysis
  • 10.9 China Anti-infective Vaccines Market Analysis
  • 10.10 India Anti-infective Vaccines Market Analysis
  • 10.11 Australia Anti-infective Vaccines Market Analysis
  • 10.12 South Korea Anti-infective Vaccines Market Analysis
  • 10.13 Singapore Anti-infective Vaccines Market Analysis
  • 10.14 Rest of Asia Pacific Anti-infective Vaccines Market Analysis

11 Latin America Anti-infective Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America Anti-infective Vaccines Market Attractiveness Index
  • 11.3 Latin America Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Country
  • 11.5 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 11.6 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 11.7 Latin America Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 11.8 Brazil Anti-infective Vaccines Market Analysis
  • 11.9 Mexico Anti-infective Vaccines Market Analysis
  • 11.10 Argentina Anti-infective Vaccines Market Analysis
  • 11.11 Colombia Anti-infective Vaccines Market Analysis
  • 11.12 Rest of Latin America Anti-infective Vaccines Market Analysis

12 MEA Anti-infective Vaccines Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA Anti-infective Vaccines Market Attractiveness Index
  • 12.3 MEA Anti-infective Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Country
  • 12.5 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 12.6 MEA Anti-infective Vaccines Market Size Estimation and Forecast by Application Type
  • 12.7 MEA Anti-infective Vaccines Market Size Estimation and Forecast by End-users
  • 12.8 GCC Anti-infective Vaccines Market Analysis
  • 12.9 South Africa Anti-infective Vaccines Market Analysis
  • 12.10 Rest of MEA Anti-infective Vaccines Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2022
  • 13.2 Strategic Outlook
  • 13.1 Pfizer Inc.
    • 13.1.1 Company Snapshot
    • 13.1.2 Company Overview
    • 13.1.3 Financial Analysis
      • 13.1.3.1 Net Revenue, 2017-2022
      • 13.1.3.2 R&D, 2017-2022
      • 13.1.3.3 Regional Market Shares, 2022
    • 13.1.4 Product Benchmarking
    • 13.1.5 Strategic Outlook
  • 13.2 AstraZeneca
    • 13.2.1 Company Snapshot
    • 13.2.2 Company Overview
    • 13.2.3 Financial Analysis
      • 13.2.3.1 Net Revenue, 2017-2022
      • 13.2.3.2 R&D, 2017-2022
      • 13.2.3.3 Regional Market Shares, 2022
    • 13.2.4 Product Benchmarking
    • 13.2.5 Strategic Outlook
  • 13.3 Bavarian Nordic
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2017-2022
      • 13.3.3.2 R&D, 2017-2022
      • 13.3.3.3 Regional Market Shares, 2022
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Serum Institute of India Pvt. Ltd.
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Product Benchmarking
    • 13.4.4 Strategic Outlook
  • 13.5 BioDiem
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Product Benchmarking
  • 13.6 Evotec SE
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Financial Analysis
      • 13.6.3.1 Net Revenue, 2017-2022
      • 13.6.3.2 R&D, 2017-2022
      • 13.6.3.3 Regional Market Shares, 2022
    • 13.6.4 Product Benchmarking
    • 13.6.5 Strategic Outlook
  • 13.7 Sinovac
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2017-2022
      • 13.7.3.2 R&D, 2017-2022
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Sanofi
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Product Benchmarking
    • 13.8.4 Strategic Outlook
  • 13.9 Merck KGaA
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2017-2022
      • 13.9.3.2 R&D, 2017-2022
      • 13.9.3.3 Regional Market Shares, 2022
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook
  • 13.10 CSL
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2017-2022
      • 13.10.3.2 R&D, 2017-2022
      • 13.10.3.3 Regional Market Shares, 2022
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Emergent
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2017-2022
      • 13.11.3.2 R&D, 2017-2022
    • 13.11.4 Product Benchmarking
    • 13.11.5 Strategic Outlook
  • 13.12 Mitsubishi Tanabe Pharma Corporation
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Product Benchmarking
    • 13.12.4 Strategic Outlook
  • 13.13 GSK plc
    • 13.13.1 Company Snapshot
    • 13.13.2 Company Overview
    • 13.13.3 Financial Analysis
      • 13.13.3.1 Net Revenue, 2017-2022
      • 13.13.3.2 R&D, 2017-2022
      • 13.13.3.3 Regional Market Shares, 2022
    • 13.13.4 Product Benchmarking
    • 13.13.5 Strategic Outlook
  • 13.14 Valneva SE
    • 13.14.1 Company Snapshot
    • 13.14.2 Company Overview
    • 13.14.3 Financial Analysis
      • 13.14.3.1 Net Revenue, 2017-2022
      • 13.14.3.2 R&D, 2017-2022
      • 13.14.3.3 Regional Market Shares, 2022
    • 13.14.4 Product Benchmarking
    • 13.14.5 Strategic Outlook
  • 13.15 Novavax
    • 13.15.1 Company Snapshot
    • 13.15.2 Company Overview
    • 13.15.3 Financial Analysis
      • 13.15.3.1 Net Revenue, 2017-2022
      • 13.15.3.2 R&D, 2017-2022
      • 13.15.3.3 Regional Market Shares, 2022
    • 13.15.4 Product Benchmarking
    • 13.15.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from
  • 14.2 Recommendations for Market Players
Product Code: PHA1283

List of Tables

  • Table 1 Anti-infective Vaccines Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
  • Table 2 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Anti-infective Vaccines Market Forecast by Region 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 7 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 8 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 Pneumococcal Conjugate Vaccine (PCV) Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 Other Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 Anti-infective Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 31 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 33 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 52 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 53 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 54 Latin America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 55 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 56 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 57 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 58 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 59 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 60 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 61 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 62 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 63 MEA Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 64 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 65 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 66 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 67 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 68 Strategic Outlook
  • Table 69 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 Pfizer Inc.: Product Benchmarking
  • Table 71 Pfizer: Strategic Outlook
  • Table 72 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 AstraZeneca: Product Benchmarking
  • Table 74 AstraZeneca: Strategic Outlook
  • Table 75 Bavarian Nordic: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Bavarian Nordic: Product Benchmarking
  • Table 77 Bavarian Nordic: Strategic Outlook
  • Table 78 Serum Institute of India Pvt. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 79 Serum Institute of India Pvt. Ltd.: Product Benchmarking
  • Table 80 Serum Institute of India Pvt. Ltd.: Strategic Outlook
  • Table 81 BioDiem: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 82 BioDiem: Product Benchmarking
  • Table 83 Evotec SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 84 Evotec SE: Product Benchmarking
  • Table 85 Evotec SE: Strategic Outlook
  • Table 86 Sinovac: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 87 Sinovac: Product Benchmarking
  • Table 88 Sinovac: Strategic Outlook
  • Table 89 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 90 Sanofi: Product Benchmarking
  • Table 91 Sanofi: Strategic Outlook
  • Table 92 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Merck KGaA: Product Benchmarking
  • Table 94 Merck: Strategic Outlook
  • Table 95 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 96 CSL: Product Benchmarking
  • Table 97 CSL: Strategic Outlook
  • Table 98 Emergent: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 99 Emergent: Product Benchmarking
  • Table 100 Emergent: Strategic Outlook
  • Table 101 Mitsubishi Tanabe Pharma Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 102 Mitsubishi Tanabe Pharma Corporation: Product Benchmarking
  • Table 103 Mitsubishi Tanabe Pharma Corporation: Strategic Outlook
  • Table 104 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 GSK plc: Product Benchmarking
  • Table 106 GSK: Strategic Outlook
  • Table 107 Valneva SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 Valneva SE: Product Benchmarking
  • Table 109 Valneva SE: Strategic Outlook
  • Table 110 Novavax: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Novavax: Product Benchmarking
  • Table 112 Novavax: Strategic Outlook

List of Figures

  • Figure 1 Anti-infective Vaccines Market Segmentation
  • Figure 2 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
  • Figure 3 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
  • Figure 4 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
  • Figure 5 Anti-infective Vaccines Market Attractiveness Index by Region
  • Figure 6 Anti-infective Vaccines Market: Market Dynamics
  • Figure 7 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 8 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 9 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 10 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 11 Anti-infective Vaccines Market: Porter's Five Forces Analysis
  • Figure 12 Anti-infective Vaccines Market: PEST Analysis
  • Figure 13 Anti-infective Vaccines Market by Vaccine Type: Market Attractiveness Index
  • Figure 14 Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 15 Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
  • Figure 16 Seasonal Influenza Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 17 Seasonal Influenza Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 18 Shingles Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 19 Shingles Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 20 TdaP Containing/ DTaP Primary Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 21 TdaP Containing/ DTaP Primary Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 22 Pneumococcal Conjugate Vaccine (PCV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 23 Pneumococcal Conjugate Vaccine (PCV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 24 Human Papillomavirus (HPV) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 25 Human Papillomavirus (HPV) Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 26 Rotavirus Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 27 Rotavirus Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 28 Varicella Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 29 Varicella Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 30 Meningococcal Vaccine Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 31 Meningococcal Vaccine Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 32 Other Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 33 Other Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 34 Anti-infective Vaccines Market by Application Type: Market Attractiveness Index
  • Figure 35 Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
  • Figure 36 Anti-infective Vaccines Market Share Forecast by Application Type, 2023, 2028, 2033 (%)
  • Figure 37 Viral Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 38 Viral Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 39 Bacterial Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 40 Bacterial Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 41 Anti-infective Vaccines Market by End-users: Market Attractiveness Index
  • Figure 42 Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 43 Anti-infective Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
  • Figure 44 Adult Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 45 Adult Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 46 Paediatric Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 47 Paediatric Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 48 Wide-ranging (comprehensive) vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 49 Wide-ranging comprehensive vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 50 Anti-infective Vaccines Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
  • Figure 51 Anti-infective Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 52 Anti-infective Vaccines Market by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 53 North America Anti-infective Vaccines Market Attractiveness Index
  • Figure 54 North America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 55 North America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 56 North America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 57 North America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 58 North America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 59 North America Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
  • Figure 60 North America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
  • Figure 61 North America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 62 North America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 63 U.S. Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 64 Canada Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 65 Europe Anti-infective Vaccines Market Attractiveness Index
  • Figure 66 Europe Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 67 Europe Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 68 Europe Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 69 Europe Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 70 Europe Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 71 Europe Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
  • Figure 72 Europe Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
  • Figure 73 Europe Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 74 Europe Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 75 Germany Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 76 France Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 77 UK Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 78 Italy Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 79 Spain Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 80 Russia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Rest of Europe Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 82 Asia Pacific Anti-infective Vaccines Market Attractiveness Index
  • Figure 83 Asia Pacific Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 84 Asia Pacific Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 85 Asia Pacific Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 86 Asia Pacific Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 87 Asia Pacific Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 88 Asia Pacific Anti-infective Vaccines Market Forecast by Application Type, 2023-2033 (US$ Million, AGR %)
  • Figure 89 Asia Pacific Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
  • Figure 90 Asia Pacific Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 91 Asia Pacific Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 92 Japan Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 93 China Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 94 India Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 95 Australia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 96 South Korea Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 97 Singapore Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 98 Rest of Asia Pacific Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 99 Latin America Anti-infective Vaccines Market Attractiveness Index
  • Figure 100 Latin America Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 101 Latin America Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 102 Latin America Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 103 Latin America Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 104 Latin America Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 105 Latin America Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
  • Figure 106 Latin America Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
  • Figure 107 Latin America Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 108 Latin America Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 109 Brazil Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 110 Mexico Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 111 Argentina Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 112 Colombia Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 113 Rest of Latin America Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 114 MEA Anti-infective Vaccines Market Attractiveness Index
  • Figure 115 MEA Anti-infective Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 116 MEA Anti-infective Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 117 MEA Anti-infective Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 118 MEA Anti-infective Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 119 MEA Anti-infective Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 120 MEA Anti-infective Vaccines Market Forecast by Usage Type, 2023-2033 (US$ Million, AGR %)
  • Figure 121 MEA Anti-infective Vaccines Market Share Forecast by Application Type, 2023 & 2033 (%)
  • Figure 122 MEA Anti-infective Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 123 MEA Anti-infective Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 124 GCC Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 125 South Africa Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 126 Rest of MEA Anti-infective Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 127 Pfizer Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 128 Pfizer Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 129 Pfizer Inc.: Regional Market Shares, 2022
  • Figure 130 AstraZeneca: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 131 AstraZeneca: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 132 AstraZeneca: Regional Market Shares, 2022
  • Figure 133 Bavarian Nordic: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 134 Bavarian Nordic: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 135 AstraZeneca: Regional Market Shares, 2022
  • Figure 136 Evotec SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 137 Evotec SE: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 138 Evotec: Regional Market Shares, 2022
  • Figure 139 Sinovac: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 140 Sinovac: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 141 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 142 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 143 Merck KGaA: Regional Market Shares, 2022
  • Figure 144 CSL: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 145 CSL: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 146 CSL: Regional Market Shares, 2022
  • Figure 147 Emergent: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 148 Emergent: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 149 GSK plc: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 150 GSK plc: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 151 GSK plc: Regional Market Shares, 2022
  • Figure 152 Valneva SE: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 153 Valneva SE: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 154 Valneva SE: Regional Market Shares, 2022
  • Figure 155 Novavax: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 156 Novavax: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 157 Novavax: Regional Market Shares, 2022
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!